Form 8-K - Current report:
SEC Accession No. 0000950170-25-006191
Filing Date
2025-01-16
Accepted
2025-01-16 16:05:26
Documents
12
Period of Report
2025-01-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atra-20250116.htm   iXBRL 8-K 45098
2 EX-99.1 atra-ex99_1.htm EX-99.1 30689
  Complete submission text file 0000950170-25-006191.txt   196931

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atra-20250116.xsd EX-101.SCH 24862
14 EXTRACTED XBRL INSTANCE DOCUMENT atra-20250116_htm.xml XML 4728
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 25535763
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)